GDF‐15 was significantly higher in patients with sarcopenia (P < 0.01) (Figure 1A) and patients with frailty (P < 0.001) (Figure 1B) compared with non‐sarcopenic and non‐frail patients, respectively. Here, GDF15 is linked to sarcopenia.